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Abstract
Background: In this study, we evaluated the lipocalin-2 (LIP2) and syndecan-4 (SYN4) levels in children who were
hospitalized for radiologically confirmed CAP in order to differentiate bacterial from viral infection. The results
regarding the LIP2 and SYN4 diagnostic outcomes were compared with the white blood cell (WBC) count and C
reactive protein (CRP) levels.
Methods: A total of 110 children <14 years old who were hospitalized for radiologically confirmed CAP were
enrolled. Serum samples were obtained upon admission and on day 5 to measure the levels of LIP2, SYN4, and CRP
as well as the WBC. Polymerase chain reaction of the respiratory secretions and tests on blood samples were
performed to detect respiratory viruses, Streptococcus pneumoniae, and Mycoplasma pneumoniae.
Results: CAP was considered to be due to a probable bacterial infection in 74 children (67.3 %) and due to a
probable viral infection in 16 children (14.5 %). Overall, 84 children (76.4 %) were diagnosed with severe CAP. The
mean values of the WBC count and the LIP2 and SYN4 levels did not differ among the probable bacterial, probable
viral, and undetermined cases. However, the CRP serum concentrations were significantly higher in children with
probable bacterial CAP than in those with probable viral disease (32.2 ± 55.5 mg/L vs 9.4 ± 17.0 mg/L, p < 0.05). The
WBC count was the best predictor of severe CAP, but the differences among the studied variables were marginal.
The WBC count was significantly lower on day 5 in children with probable bacterial CAP (p < 0.01) and in those
with an undetermined etiology (p < 0.01). The CRP and LIP2 levels were significantly lower 5 days after enrollment
in all of the studied groups, independent of the supposed etiology of CAP (p < 0.01 for all comparisons). No
statistically significant variation was observed for SYN4.
Conclusions: Measuring the LIP2 and SYN4 levels does not appear to solve the problem of the poor reliability of
routine laboratory tests in defining the etiology and severity of pediatric CAP. Currently, the CRP levels and WBC,
when combined with evaluation of clinical data, can be used to limit the overuse of antibiotics as much as possible
and to provide the best treatment to the patient.
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Background
Community-acquired pneumonia (CAP) is one of the
leading causes of morbidity and mortality in young chil-
dren worldwide [1]. Viruses and bacteria, either alone or
in combination, are the primary causes of CAP [2, 3].
Early detection of bacterial cases is essential to guide
clinical management and avoid prolonged hospitalization,
complications and the risk of death [4]. Furthermore, dif-
ferentiation of viral CAP from bacterial CAP is the basis
for the rational administration of antibiotics, the reduction
in the use of antibiotics and the consequent reduction of
the emergence of bacterial resistance and drug-related ad-
verse events [5, 6]. Unfortunately, these goals are difficult
to attain, particularly in children in whom the collection
of respiratory samples is either difficult or impossible [6].
The clinical signs, symptoms and radiological findings are
frequently similar in viral and bacterial diseases. Moreover,
in most cases, the results of routine laboratory tests,
including white blood cell (WBC) count and serum C-
reactive protein (CRP) levels, tend to overlap, making dif-
ferentiation between viral and bacterial infection impos-
sible [7, 8]. These limitations explain why several attempts
to find more effective markers of bacterial etiology and
the severity of CAP have been made in recent years.
Recently, it has been suggested that lipocalin-2 (LIP2),
also known as neutrophil gelatinase-associated lipocalin
(NGAL), and syndecan-4 (SYN4) could be useful to
diagnose bacterial and severe CAP [9–12]. LIP2 is a pro-
tein that is stored in the granules of human neutrophils
and has been described as a component of the innate
immune system and the acute phase response to infec-
tion [13]. This protein plays a relevant role in innate
defense primarily by interfering with bacterial iron up-
take [14]. LIP2-deficient animals exhibit higher mortality
rates compared to control animals when they are chal-
lenged with pathogenic bacteria [14, 15]. Moreover, LIP2
is upregulated in inflammatory states [15], and its ex-
pression is strongly increased in bronchial epithelial cells
and alveolar type 2 pneumocytes of animals exposed to
bacterial pathogens [16]. Viral infections did not seem to
influence LIP2 levels [13–15].
SYN4 is a heparin sulfate proteoglycan that is
expressed on the surface of a variety of cells, including
macrophages, epithelial cells, endothelial cells, and fi-
broblasts [17, 18]. SYN4 binds to several cytokines,
chemokines, and growth factors and mediates their
biological activity. SYN4 expression is rapidly increased
in response to bacterial infection and not to viral infec-
tion [17, 18]. SYN4-deficient animals have an increased
risk of negative evolution when exposed to bacteria
[19]. Finally, pre-treatment of lung epithelial cells with
SYN4 was observed to inhibit the inflammatory prop-
erties of bacterial components such as lipopolysaccha-
rides and proinflammatory cytokines [11].
Data collected in humans regarding these proteins are
scarce, and the real role of LIP2 and SYN4 as bio-
markers for defining the etiology and severity of CAP is
poorly defined. No data on these new biomarkers are
available in children and due to their characteristics they
appear attractive in the possibility to differentiate bacter-
ial from viral CAP. However, it is unclear whether the
inclusion of routine laboratory tests detecting these pro-
teins could be useful in routine clinical practice. This
study was planned to evaluate the LIP2 and SYN4 levels
in a group of children who were hospitalized in pediatric
ward for radiologically confirmed CAP in order to dif-
ferentiate bacterial from viral infection. The results re-
garding the diagnostic performances of LIP2 and SYN4
were compared with those of the WBC count and
serum CRP levels.
Methods
Patient enrolment
This study was carried out at the Pediatric Highly Inten-
sive Care Unit of the University of Milan, Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, be-
tween November 1, 2014, and April 30, 2015, and was ap-
proved by the Ethics Committee of the Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico in Milan, Italy.
Written informed consent was obtained from either the
parent(s) or legal guardian(s) of each study participant,
and the children who were aged >8 years signed their writ-
ten assent.
Only otherwise healthy children below 14 years of age
with clinical signs such as tachypnea and abnormal
breath sounds that suggested CAP and who required
hospitalization were recruited. The CAP diagnoses were
confirmed by chest radiography, as evaluated by an in-
dependent expert radiologist, who classified the find-
ings as alveolar pneumonia, non-alveolar pneumonia,
or no pneumonia in accordance with the World Health
Organization criteria for the standardized interpretation
of pediatric chest radiographs for a diagnosis of pneu-
monia [20]. Alveolar pneumonia was defined as dense
opacity appearing as fluffy consolidation of either part
or all of a lobe, or an entire lung, often containing air
on bronchography and occasionally associated with
pleural effusion.
Disease severity was established following the criteria
indicated for children by the British Thoracic Society [21].
In particular, the features of severe disease in an infant
were as follows: oxygen saturation <92 %; cyanosis; re-
spiratory rate >70 breaths/min; significant tachycardia for
level of fever; prolonged central capillary refill time >2 s;
difficulty breathing; intermittent apnea or grunting; and
not feeding. The features of severe disease in an older
child included the following: oxygen saturation <92 %;
cyanosis; respiratory rate >50 breaths/min; significant
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tachycardia for level of fever; prolonged central capillary
refill time >2 s; difficulty in breathing; grunting; and signs
of dehydration.
After enrollment, the demographics, clinical history
and clinical disease characteristics of each child were
recorded. Moreover, a blood sample was collected for
routine laboratory testing, including WBC count,
serum CRP levels, blood culture and LIP2 and SYN4
levels. The sample was divided into two aliquots; the
first was sent to the central laboratory of the hospital
for routine testing, including WBC count, serum CRP
levels and blood culture, whereas the second aliquot
was sent to a research laboratory to measure the serum
LIP2 and SYN4 concentrations and to detect Strepto-
coccus pneumoniae and Mycoplasma pneumoniae DNA.
Moreover, a nasopharyngeal sample was obtained using
a pernasal nylon flocked swab and stored in a tube of
universal transport medium (Kit Cat. No. 360c, Copan
Italia, Brescia, Italy) for virus, S. pneumoniae, and M.
pneumoniae detection.
All of the hospitalized children were treated according
to international guidelines [22]. The clinical data col-
lected during hospitalization were recorded daily, and all
of the enrolled children were re-evaluated after 5 days
by means of interviews and clinical examinations per-
formed by trained investigators using standardized ques-
tionnaires. A second blood sample was drawn during the
visits on day 5 to determine the WBC count and the
serum concentrations of CRP, LIP2, and SYN4.
LIP2 and SYN4 determination
Freshly thawed aliquots of serum samples were used
for LIP2 and SYN4, and their analyses were performed
by two different commercial enzyme-linked immuno-
sorbent assay (ELISA) kits: a human LIP2 ELISA kit
(Biolegend, San Diego, CA, USA) and a human SYN4
ELISA Kit (CUSABIO Life Science Biotech Co., Hubei
Province, China); both kits were used according to the
manufacturer’s instructions. All of the serum samples
were clear and non-hemolyzed. The average minimum
detectable concentration of the human LIP2 kit was
16.4 ng/mL and the minimum detectable level of the
human SYN4 kit was less than 0.10 ng/mL.
Viral analyses
Viral RNA or DNA was extracted from the respiratory se-
cretions by means of a NucliSENS EasyMAG automated
extraction system (Biomeriéux, Craponne, France) and
was then tested using the Luminex xTAG respiratory virus
panel fast assay (Luminex Molecular Diagnostics Inc.,
Toronto, Canada) to detect influenza A virus (subtypes
H1 or H3); influenza B virus; respiratory syncytial virus
(RSV) A and B; parainfluenzavirus-1, 2, 3, and 4; adeno-
virus, human metapneumovirus; coronaviruses 229E,
NL63, OC43, and HKU1; enterovirus/rhinovirus (RV) and
human bocavirus [23–25] in accordance with the manufac-
turer’s instructions. The enterovirus/RV-positive samples
were retested by means of a real-time polymerase chain
reaction (PCR) assay using the iAg-Path-ID one-step real-
time PCR kit (Applied Biosystems, Foster City, CA, USA),
and the primers and probe sequences reported by Lu et al.
[26] to identify the RV.
The remaining amounts of nucleic acid extracts were
used for bacterial analyses.
Identification of Streptococcus pneumoniae and
Mycoplasma pneumoniae
In addition to blood culture (that included also
Staphylococcus aureus culture), advanced methods for
research of the two main pathogens (i.e., S. pneumoniae
and M. pneumoniae) involved in the etiology of pediatric
CAP were performed.
To identify the pneumococcal cases, the nasopharyn-
geal samples and the blood collected upon hospital ad-
mission were tested for the autolysin-A (LytA) and wzg
(cpsA) genes of S. pneumoniae using real-time PCR as
previously described [27]. Each sample was tested in
triplicate and was considered positive if at least two of
the three replicates were positive. To maximize sensitiv-
ity, no internal amplification control was used in the re-
action, but an external control was used.
In the nasopharyngeal samples and the blood collected
at admission, M. pneumoniae DNA was tested with a
validated nested PCR as previously described [28].
Identification of probable bacterial and viral infection
CAP was considered to be of probable bacterial origin
under two criteria: 1) detection of any bacteria in blood
culture or detection of S. pneumoniae or M. pneumoniae
either in the blood or in a nasopharyngeal swab positive
in absence of viral detection and 2) a chest radiograph
suggesting alveolar CAP.
Probable viral CAP was diagnosed in presence of a
nasopharyngeal swab positive for one or more respira-
tory viruses in absence of bacterial detection and in as-
sociation with a chest radiograph leading to diagnosis of
non-alveolar CAP.
Undetermined cases included those with both bacterial
and viral pathogens or those with no pathogen detected.
Statistical analysis
Descriptive statistics of the responses were generated.
Continuous variables were presented as the mean values ±
standard deviation (SD) and the categorical variables as
numbers and percentages. For categorical data, compari-
sons between groups were performed using the contin-
gency table analysis with either the χ2 or Fisher’s exact test
as appropriate. Continuous data were analyzed using
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either a two-sided Student’s t-test after determining that
the data were normally distributed (based on the Shapiro-
Wilk statistic) or a two-sided Wilcoxon’s rank-sum test.
Diagnostic performances of the biomarkers were eval-
uated via receiver operating characteristic (ROC) curves
and the area under the ROC curve (AUC). The best
cutoff values for different biomarkers were obtained
based on the highest sensitivity and specificity using
the roctab function in STATA. Odds ratios (OR) and
95 % confidence intervals (CI) were calculated to meas-
ure the association between biomarkers and the follow-
ing dependent variables: 1) probable bacterial etiology;
2) probable viral etiology; and 3) disease severity. ORs
were obtained using unconditional multiple logistic re-
gression and were adjusted for age, sex, ethnicity, edu-
cation of parents, and smoking habits of parents.
All analyses were conducted using SAS version 9.2
(Cary, NC, USA) and STATA version 11.0 (StataCorp
LP, College Station, TX, USA).
Results
A total of 110 children (males, 61 [55.4 %]; mean age 4.8 ±
3.4 years) were enrolled. Their demographic, clinical, and
laboratory characteristics are reported in Table 1. CAP was
considered due to a probable bacterial infection in 74 chil-
dren (67.3 %) and a probable viral infection in 16 children
(14.5 %). In 20 cases (18.2 %), it was not possible to iden-
tify the probable etiology of the disease; these patients
were defined as undetermined. Overall, 84 (76.4 %) chil-
dren had severe CAP. The mean values of the WBC count
and LIP2 and SYN4 levels did not differ between probable
bacterial, probable viral, and undetermined cases. How-
ever, the serum CRP concentrations were significantly
higher in children with probably bacterial CAP than in
those with probable viral disease (32.2 ± 55.5 mg/L vs
9.4 ± 17.00 mg/L, p < 0.05).
Table 2 summarizes microbiological findings in chil-
dren classified as probable bacterial or probable viral in-
fection. Blood culture was negative in all the cases.
Probable bacterial infections were due to S. pneumoniae
(59 cases) or to M. pneumoniae (15 cases). Probable viral
infections were due to RSV (12 cases), metapneumovirus
(2 cases) and influenza A (2 cases).
Table 3 shows the diagnostic performance of the four
studied biomarkers to discriminate bacterial and viral in-
fections and identify severe CAP according to biomarker
cut-off with the highest sensitivity and specificity. As evi-
denced by the AUC, all of the biomarkers were insufficient
Table 1 Demographic, clinical, and laboratory variables in 110 children hospitalized for radiologically confirmed community-
acquired pneumonia according to their infection status
All subjects Probable bacterial Probable viral Undetermined
n = 110 n = 74 n = 16 n = 20
Demographics and clinical presentation
Males (%) 61 (55.4) 45 (60.8)* 5 (31.2)* 11 (55.0)
Mean age ± SD (years) 4.8 ± 3.4 5.1 ± 3.4 3.6 ± 2.8 4.9 ± 3.5
Caucasians (%)a 95 (88.8) 62 (87.3) 13 (81.2) 20 (100.0)
At least one parent smoked (%)a 28 (25.9) 19 (26.0) 5 (31.2) 4 (21.0)
Presence of fever” (%) 91 (82.7) 64 (86.5) 12 (75.0) 15 (75.0)
O2 therapy (%)
a 26 (25.2) 14 (19.7)* 7 (50.0)* 5 (27.8)
Clinical findings (%)
Rhonchi 12 (10.9) 5 (6.8) 3 (18.7) 4 (20.0)
Rales 92 (83.6) 63 (85.1) 14 (87.5) 15 (75.0)
Wheezing 21 (19.1) 11 (14.9) 3 (18.7) 7 (35.0)
Any of the above 96 (87.3) 64 (86.5) 15 (93.7) 17 (85.0)
Severe disease 84 (76.4) 59 (79.7) 12 (75.0) 13 (65.0)
Laboratory data
WBC (cells/μL)a 15,741 ± 8,575 16,573 ± 8,969 13,674 ± 7338 14,358 ± 7,899
Neutrophils, %a 66.1 ± 19.3 68.3 ± 18.4 65.2 ± 17.8 59.2 ± 22.9
CRP, μg/dLa 25.5 ± 47.4 32.2 ± 55.5* 9.4 ± 17.0* 14.0 ± 19.4
LIP2, ng/mL 2,079 ± 1,606 2,158 ± 1,744 1,880 ± 1,015 1,946 ± 1,488
SYD4, ng/mL 5.08 ± 3.95 5.27 ± 4.10 4.31 ± 3.06 4.99 ± 4.14
CRP C-reactive protein, LIP2 lipocalin-2, SD standard deviation, SYD4 syndecan-4, WBC white blood cell count
*p < 0.05 between probable bacterial and probable viral infection groups. No other statistically significant differences between groups were observed
aSome missing values (two cases in probable bacterial CAP, two in probable viral CAP and two in undetermined CAP)
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to identify probable bacterial and probable viral cases. Re-
garding probable bacterial infections, CRP level was the
best predictor. A serum CRP concentration ≥7.4 mg/L
was observed to be associated with a sensitivity of 64.4 %
and a specificity of 69.4 %, leading to a positive predictive
value (PPV) of 81 % and a negative predictive value (NPV)
of 49 %. The AUC was 0.65 (95 % CI 0.53-0.76). Both
LIN2 and SYN4 had lower predictive ability. For both, the
AUC was low (0.51, 95 % CI 0.40-0.63 for LIN2 and 0.54,
95 % CI 0.42-0.65 for SYN4). However, whereas the cutoff
value of LIP2 (1,633 ng/mL) had limited sensitivity and
specificity (58.1 % and 50.0 %, respectively), that of SYN4
(≥7.25 ng/mL) was shown to have very low sensitivity
(31.1 %) but very high specificity (86.1 %), leading to a
PPV of 82.1 % and to a NPV of 37.8 %. The AUC for
the WBC count was 0.57 (95 % CI 0.46-0.69). The cut-
off value of the WBC count (≥10,300) had a sensitivity
of 74 %, a specificity of 38.9 %, a PPV of 71.1 %, and a
NPV of 42.4 %.
CRP also remained the best predictor in the case of
probable viral infection, although with marginal differ-
ences compared with the other studied parameters. The
AUC for CRP was 0.67 (95 % CI 0.53-0.80) compared to
0.56 (95 % CI 0.42-0.70) for the WBC count, 0.50 (95 %
CI 0.37-0.64) for LIP2, and 0.54 (95 % CI 0.40-0.69) for
SYN4. All of the biomarkers had sensitivity but very low
specificity, which led to an excellent NPV but low PPV.
The WBC count was the best predictor of severe CAP
but differences among the studied variables were mar-
ginal. The AUC for the WBC count was 0.71 (95 % CI
0.59-0.83) compared to 0.65 (95 % CI 0.51-0.79) for CRP,
Table 2 Frequency of infections detected among children
hospitalized for radiologically confirmed community-acquired
pneumonia and probable bacterial or probable viral infection
Type of infection n (%)
Probable bacterial 74
Streptococcus pneumoniae infection (swab only) 59/74 (79.7)
Mycoplasma pneumoniae infection (swab only) 15/74 (20.3)
Probable viral 16
Respiratory syncytial virus 12/16 (75.0)
Metapneumovirus 2/16 (12.5)
Influenza A 2/16 (12.5)
Table 3 Diagnostic performance of lipocalin-2 and syndecan-4 biomarkers compared to white blood cell count and C reactive
protein at time of enrollment in 110 children hospitalized for radiologically confirmed community-acquired pneumonia to predict
infections and severity of disease, and odds ratio and 95 % confidence interval according to the biomarker cut-off with the highest
sensitivity and specificity
Biomarker cut-off value Sensitivity Specificity PPV NPV AUC (95 % CI) OR (95 % CI)***
S. pneumoniae infection (n = 59)
LIP2 ≥1,633 71.2 % 62.7 % 68.9 % 65.3 % 0.62 (0.51-0.73) 4.26 (1.76-10.3)
SYN4a ≤1.78 28.8 % 80.4 % 63.0 % 49.4 % 0.50 (0.39-0.61) 1.78 (0.62-5.15)
WBC ≥13,500 63.8 % 68.6 % 69.8 % 62.5 % 0.66 (0.55-0.76) 3.91 (1.50-10.2)
CRP ≥12.3 58.6 % 68.6 % 68.0 % 59.3 % 0.63 (0.52-0.74) 2.59 (1.03-6.54)
Probable bacterial infection (n = 74)
LIP2 ≥1,633 58.1 % 50.0 % 70.5 % 36.7 % 0.51 (0.40-0.63) 1.21 (0.49-2.99)
SYN44 ≥7.25 31.1 % 86.1 % 82.1 % 37.8 % 0.54 (0.42-0.65) 5.54 (1.56-19.7)
WBC ≥10,300 74.0 % 38.9 % 71.1 % 42.4 % 0.57 (0.46-0.69) 1.90 (0.72-4.97)
CRP ≥7.4 64.4 % 69.4 % 81.0 % 49.0 % 0.65 (0.53-0.76) 3.35 (1.30-8.63)
Probable viral infection (n = 16)
LIP2 ≥896 87.5 % 28.7 % 17.3 % 93.1 % 0.50 (0.37-0.64) 3.50 (0.61-20.1)
SYN4a ≤5.64 81.2 % 37.2 % 18.1 % 92.1 % 0.54 (0.40-0.69) 7.16 (1.20-42.6)
WBCa ≤19,710 93.7 % 28.0 % 18.3 % 96.3 % 0.56 (0.42-0.70) 8.02 (0.75-85.1)
CRPa ≤5.2 75.0 % 64.5 % 26.7 % 93.7 % 0.67 (0.53-0.80) 5.95 (1.44-24.7)
Severe disease (n = 84)
LIP2 ≥783 83.3 % 50.0 % 84.3 % 48.1 % 0.64 (0.50-0.78) 5.45 (1.83-16.2)
SYN4a ≤5.83 71.4 % 50.0 % 82.2 % 35.1 % 0.58 (0.44-0.71) 4.37 (1.40-13.6)
WBC ≥11,170 73.5 % 69.2 % 88.4 % 45.0 % 0.71 (0.59-0.83) 8.34 (2.61-26.7)
CRP ≥4.56 67.5 % 61.5 % 84.8 % 37.2 % 0.65 (0.51-0.79) 2.72 (0.98-7.57)
95 % CI confidence interval, CRP C reactive protein, LIP2 lipocalin-2, OR odds ratio, SYN4 syndecan-4 (SYN4), WBC white blood cell count
Logistic regression model adjusting for age, sex, study center, ethnicity, parental education, and parental smoking habit
aInverse relationship between biomarker and infection/severity of disease
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0.64 (95 % CI 0.50-0.78) for LIP2, and 0.58 (95 % CI
0.44-0.71) for SYN 4. LIP2 had the highest sensitivity of
the cutoff values (83.3 %), with CRP having the lowest
(67.5 %). The PPV values were 88.4 % for the WBC
count, 84.8 % for CRP, 84.3 % for LIP2, and 82.2 % for
SYN4. The NPV was low for all of the biomarkers.
All of the enrolled subjects showed significant im-
provement of their clinical conditions upon examination
5 days after enrollment. Table 4 summarizes the mean
values of the studied biomarkers at 5 days after enroll-
ment and the corresponding variations compared to the
baseline data based on infection status. The WBC count
was significantly lower on day 5 in children with prob-
able bacterial CAP (p < 0.01) and in those with undeter-
mined etiology (p < 0.01). CRP levels were significantly
lower after 5 days from enrollment in all of the studied
groups independent from the supposed etiology of CAP
(p < 0.01 for all of the comparisons). The same was true
for the LIP2 levels (p < 0.01). No statistically significant
variations were observed for SYN4.
Discussion
CAP is a significant clinical problem in children despite
the availability of effective antibiotics and vaccines [3, 6].
Early identification of CAP cases due to bacterial infec-
tion or that are likely to become severe is critical to en-
sure appropriate treatment. Unfortunately, this study
shows that in the studied pediatric population, neither
LIP2 nor SYN4 were superior to CRP and the WBC
count in predicting the etiology and severity of CAP and
in the evaluation of disease course. Upon enrollment,
the mean serum values of both LIP2 and SYN4 were
similar in children with probable bacterial and probable
viral infections. Moreover, the cut-offs with the highest
sensitivity and specificity were either marginally or inef-
fective in identifying the etiology and predicting the se-
verity. Although with suboptimal efficiency, CRP was
associated with the highest efficiency in identifying bac-
terial and viral cases, and the WBC count was the most
efficient biomarker in defining disease severity. More-
over, 5 days after diagnosis, when all of the enrolled sub-
jects had shown significant clinical improvement, LIP2
had a reduction substantially similar to that observed in
CRP and the WBC count, whereas SYN4 was insignifi-
cantly reduced. These findings do not support the use of
these biomarkers in the routine clinical practice for
identifying the probable etiology of a CAP case, defining
its severity and evaluating its course. CRP and the WBC
count provide slightly better information (particularly
CRP), are included in laboratory tests routinely per-
formed by all the hospital laboratories and are less ex-
pensive than testing for LIP2 and SYN4.
These conclusions are different from those reported
by other authors. Nikaido et al. conducted a mass
spectrometry-based proteomic study to identify and
validate markers of bacterial etiology and severity of
CAP in African children and reported that LIP2 could
be effective for the identification of bacterial and severe
cases [12]. However, the study population and methods
used to evaluate the biomarkers were different, which
could explain the contradictory results. In this study,
otherwise healthy children hospitalized for CAP were
Table 4 Lipocalin-2 and syndecan-4 biomarkers at enrollment and corresponding variations after 5 days among 110 children
hospitalized for radiologically confirmed community-acquired pneumonia according to their infection status
All subjects Probable bacterial £ Probable viral # Undetermined
Biomarker n = 110 n = 74 n = 16 n = 20
White blood cell at enrolment (cells/μL) 15,741 ± 8,575 16,573 ± 8,969 13,674 ± 7,338 14,358 ± 7,899
White blood cell after 5 days (cells/μL)a 9,623 ± 4,437 9,546 ± 4,817 10,396 ± 2,726 9,471 ± 3,942
Variation in white blood cell (cells/μL)a −6,488 ± 9,680** −7,505 ± 10,277** −2,927 ± 8,310 −4,991 ± 7,899**
CRP at enrolment, μg/dL 25.5 ± 47.4 32.2 ± 55.5*** 9.4 ± 17.0*** 14.0 ± 19.4
CRP after 5 days, μg/dLa 6.8 ± 17.4 9.4 ± 20.7*** 1.2 ± 1.9*** 1.7 ± 3.3
Variation in CRP, μg/dLa −20.2 ± 43.5** −25.0 ± 51.4** −6.6 ± 14.1** −12.3 ± 16.7**
LIP2 at enrolment 2,079 ± 1,606 2,158 ± 1,744 1,880 ± 1,015 1,946 ± 1,488
LIP2 after 5 days 1,163 ± 1,015 1,195 ± 1,102 1,236 ± 828 986 ± 814
Variation in LIP2 −915 ± 1526** −962 ± 1666** −644 ± 583** −959 ± 1532*
SYN4 at enrolment 5.08 ± 3.95 5.27 ± 4.10 4.31 ± 3.06 4.99 ± 4.14
SYN4 after 5 days 5.68 ± 4.29 5.71 ± 4.56 4.48 ± 3.08 6.53 ± 4.06
Variation in SYN4 0.59 ± 2.81 0.43 ± 2.75 0.17 ± 2.54 1.54 ± 3.17*
CRP C reactive protein, LIP2 lipocalin-2, OR odds ratio, SD standard deviation, SYN4 syndecan-4, WBC white blood cell count
*p < 0.05 between enrollment and day 5
**p < 0.01 between enrollment and day 5
***p < 0.05 between probable bacterial and probable viral infection groups. No other statistically significant differences between the groups were found
aData at day 5 regarding white blood cells were available for 92 subjects and CRP were available for 94 subjects
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enrolled, whereas Huang et al. evaluated subjects that
in many cases were suffering from malaria, acquired
immunodeficiency infection and malnutrition; all con-
ditions that, as stated by the authors themselves, can
significantly modify the LIP2 response [10]. Moreover,
in our study, the criteria used to define probable bac-
terial and probable viral CAP and those used to define
severe disease were more stringent. Data regarding the
detection of respiratory bacteria and viruses in naso-
pharyngeal samples were associated with evaluated
radiological findings according to the World Health
Organization standardizations [20], whereas severity was
established using the criteria suggested by the British
Thoracic Society [21]. The results of this study are also
different from those reported by Yeh et al. in adults in
whom LIP2 was shown to predict the severity of CAP [9].
However, in this study, the criteria used to define severity
were again different because pediatric criteria for the
evaluation of CAP severity are not the ones used in adults.
Regarding SYN4, the data collected by Nikaido et al.
in a small number of adults with CAP have shown that
an increase in this biomarker could be observed only in
subjects with mild disease, whereas its concentrations
were similar to those found in healthy subjects when
measured in patients with severe CAP [12]. Moreover,
the serum levels of SYN4 were increased in patients who
received antibiotics for a short period of time but not in
those with long-term treatment [12]. That study was
retrospective, and the criteria used for defining CAP se-
verity were not stringent. Consequently, no comparison
with the data collected in our study is possible.
In our study, serum CRP levels were the best predictor
of etiology and WBC count the best predictor of sever-
ity. The potential use of CRP in differentiating bacterial
from non-bacterial lower respiratory tract infection has
been repeatedly suggested [28–31]. Similarly, WBC count
is commonly used to identify among children with fever
without source those who need antibiotic treatment be-
cause they are at risk of severe invasive bacterial infection
[32]. However, none of these biomarkers can be consid-
ered the best solution for guiding clinical management of
CAP in infants and children. CRP, as a type of acute phase
reaction protein, is closely related to the inflammatory re-
action and tissue injuries and can be significantly influ-
enced by factors different from bacterial components [33].
For many years, it has been shown that only extremely
high CRP serum levels are associated with bacterial dis-
ease and negative prognosis, whereas in many cases, these
values do not allow the real etiology of the disease to be
determined [28–31]. Similar conclusions are valid for the
WBC count [28–31]. Among the attempts made in recent
years to solve the problem of a prompt and effective
supposition of the probable etiology of CAP, those in-
volving procalcitonin evaluation appear to be the most
reliable in suggesting etiology [34, 35]. Moreover, varia-
tions in procalcitonin concentrations can be used to es-
tablish a therapy response and antibiotic administration
schedule [36]. However, in this study we did not evalu-
ate procalcitonin because it was not available in routine
practice in our hospital.
Limitations of this study include the fact that bacterial
and viral detection in the upper respiratory tract could
theoretically be positive also in asymptomatic carriers,
only hospitalized children were evaluated, the study
had descriptive purposes and the number of probable
viral infections was quite low. However, the distribution
of etiology seems to reflect results already obtained in
hospitalized children [25, 27, 28] and the fact that we
tried to differentiate bacterial and viral infections is a
major strength of this research because previous studies
were only focused on the use of the biomarkers in bac-
terial infection.
Conclusions
This study indicates that the use of routine laboratory
testing of LIP2 and SYN4 does not appear to be capable
of defining the etiology of CAP in children. However,
before definitively excluding the use of these bio-
markers, further studies are needed. In lieu of a defini-
tive answer, CRP and the WBC count, combined with
adequate evaluation of clinical data, must be used in
the attempt to limit the irrational use of antibiotics as
much as possible and concurrently ensure the best
treatment for the patient.
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